Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | KCNT1 | Q5JUK3 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997610 | 0.94 | PSMB8 (0.53) | FAAHPSMB8PSMB9PSMB5LMNA | |
| SCHEMBL17162239 | 0.94 | FAAH (0.50) | FAAHPSMB8PSMB9PSMB5LMNA | |
| SCHEMBL21678941 | 0.91 | FAAH (0.45) | FAAHPSMB8PSMB9PSMB5LMNA | |
| SCHEMBL21678892 | 0.85 | FAAH (0.42) | FAAHPSMB8PSMB9PSMB5LMNA | |
| SCHEMBL25470787 | 0.85 | SMN1; SMN2 (0.43) | FAAHSMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL19635164 | 0.84 | FAAH (0.50) | FAAHSMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL15273648 | 0.83 | PSMB8 (0.46) | FAAHPSMB8PSMB9PSMB5KDM4E | |
| SCHEMBL21679322 | 0.82 | FAAH (0.39) | FAAHPSMB8PSMB9PSMB5LMNA | |
| SCHEMBL23012314 | 0.81 | KDM4E (0.40) | FAAHLMNASMN1; SMN2RAB9AKDM4E | |
| SCHEMBL17384041 | 0.81 | FAAH (0.52) | FAAHLMNAKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4031552-B1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-06 | — | — | EP | disclosed |
| CN-118488947-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023141852-A1 | CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF | 益方生物科技(上海)股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2022250069-A1 | SULFUR-CONTAINING PYRAZOLE COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT INCLUDING SULFUR-CONTAINING PYRAZOLE COMPOUND AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2022-12-01 | — | — | WO | disclosed |
| EP-4031552-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| CN-114728975-A | Azole-fused pyridazin-3 (2H) -one derivatives | 武田药品工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021055326-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | WO | disclosed |
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8937150-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-2352723-A2 | HALOGEN-SUBSTITUTED COMPOUNDS USED AS PESTICIDES | Bayer CropScience AG (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010051926-A2 | NEW HALOGEN-SUBSTITUTED BONDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | GPR139, GPR119, GPR39 | FAAH 3723/4885PSMB8 3337/4885PSMB9 2267/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | FAAH 3723/4885PSMB8 3337/4885PSMB9 2267/4885 |
| US-20110301181-A1 | halogen-substituted compounds | L3MBTL4, QSOX1, L3MBTL3 | FAAH 1671/4885PSMB8 2927/4885PSMB9 2713/4885 |
| US-20150099766-A1 | Novel halogen-substituted compounds | L3MBTL4, PRDX4, PRDX1 | FAAH 1902/4885PSMB8 3161/4885PSMB9 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.